Gene Therapies: US FDA Sticks With Bleeding Rate For Hemophilia Approval Endpoint
Executive Summary
Although clotting factor activity levels may someday be validated as a surrogate endpoint, the currently recommended primary efficacy measure for traditional approval remains annualized bleeding rate, agency says in final guidance.
You may also be interested in...
Rare Disease Gene Therapy Guidance Gives More Flexibility On Placebo-Controlled Trials
US FDA declined stakeholder requests to remove recommendation for placebo controls from a final guidance but added qualifying language on their use ‘when feasible.’ While the agency excised language on biomarker validation from the final guidance, it reaffirmed the need for early establishment of critical quality attributes and critical process parameters.
Hemophilia Accelerated Approval: Factor Activity Useful Surrogate, Panel Says
Variability in assays is important issue in managing patients at “trough” levels, experts at US FDA hemophilia workshop suggest. However, assuming some significant level of activity is restored, the exact level isn’t overly important.
Hemophilia Gene Therapy Studies Could Use Non-Inferiority Design, US FDA Suggests
Development guidance from CBER recommends comparing investigational gene therapy products to existing prophylaxis treatment.